Folio Search · free preview

Papers on “cancer immunotherapy checkpoint inhibitors”

Live results from Semantic Scholar, CrossRef and OpenAlex — no account needed to look.

1. PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

   Andreas Daniel Hartkopf, Florin‐Andrei Taran, Markus Wallwiener, et al. · 2016 · Breast Care · 30,914 cites

   Immune checkpoint inhibition represents a major recent breakthrough in the treatment of malignant diseases including breast cancer. Blocking the programmed death receptor-1 (PD-1) and its ligand, PD-L1, has shown impressive antitumor activity and may lead to durable long-term disease control, especially in the triple-negative subtypes of breast cancer (TNBC). Although immune checkpoint blockade is generally well tolerated, specific immune-related adverse events (irAEs) may occur. This review summarizes the clinical efficacy, perspectives, and future challenges of using PD-1/PD-L1-directed antibodies in the treatment of breast cancer.

2. Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

   Rimda Wanchoo, Sabine Karam, Nupur N. Uppal, et al. · 2017 · American Journal of Nephrology · 15,286 cites

   BACKGROUND: Cancer immunotherapy, such as anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed death 1 (PD-1), has revolutionized the treatment of malignancies by engaging the patient's own immune system against the tumor rather than targeting the cancer directly. These therapies have demonstrated a significant benefit in the treatment of melanomas and other cancers. SUMMARY: In order to provide an extensive overview of the renal toxicities induced by these agents, a Medline search was conducted of published literature related to ipilimumab-, pembrolizumab-, and nivolumab-induced kidney toxicity. In addition, primary data from the initial clinical trials of these age

3. Tumor mutational load predicts survival after immunotherapy across multiple cancer types

   Robert M. Samstein, Chung‐Han Lee, Alexander Noor Shoushtari, et al. · 2019 · Nature Genetics · 4,458 cites

4. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

   Jonathan J. Havel, Diego Chowell, Timothy An-thy Chan · 2019 · Nature reviews. Cancer · 2,397 cites

5. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

   on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Igor J. Puzanov, Adi Diab, et al. · 2017 · Journal for ImmunoTherapy of Cancer · 2,019 cites

   Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse events (irAEs). Many of these are driven by the same immunologic mechanisms responsible for the drugs' therapeutic effects, namely blockade of inhibitory mechanisms that suppress the immune system and protect body tissues from an unconstrained acute or chronic immune response. Skin, gut, endocrine, lung and musculoskeletal irAEs are relatively common, whereas cardiovascular, hematologic, renal, neurologic and ophthalmologic irAEs occur much less f

6. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs

   Alyson Haslam, Vinay K. Prasad · 2019 · JAMA Network Open · 1,457 cites

   Importance: Immunotherapy checkpoint inhibitors have generated considerable interest because of durable responses in a number of hitherto intractable tumor types. Objective: To estimate the percentage of patients with cancer in the United States who are eligible for and respond to checkpoint inhibitor drugs approved for oncology indications by the US Food and Drug Administration (FDA). Design, Setting, and Participants: Retrospective cross-sectional study performed from June 2018 through October 2018 using publicly available data to determine (1) demographic characteristics of patients with advanced or metastatic cancer, (2) FDA data on checkpoint inhibitors approved from January 2011 throug

7. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

   Julie Renee Brahmer, Hamzah Abu‐Sbeih, Paolo A. Ascierto, et al. · 2021 · Journal for ImmunoTherapy of Cancer · 891 cites

   Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several cancers. While these immunotherapies have improved patient outcomes in many clinical settings, they bring accompanying risks of toxicity, specifically immune-related adverse events (irAEs). There is a need for clear, effective guidelines for the management of irAEs during ICI treatment, motivating the Society for Immunotherapy of Cancer (SITC) to convene an expert panel to develop a clinical practice guideline. The panel discussed the recognition and management of single and combination ICI irAEs and ultimately developed evidence- and consensus-based recommendations to assist medical professionals in cl

8. Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics

   Julianne D. Twomey, Baolin Zhang · 2021 · The AAPS Journal · 680 cites

   Immune checkpoint inhibitors (ICIs) are considered a new standard-of-care across many cancer indications. This review provides an update on ICIs approved by the Food and Drug Administration (FDA), with focus on monoclonal antibodies that target the programmed cell death 1 (PD-1) or its ligand, PD-1 ligand 1 (PD-L1), including information on their clinical indications and associated companion diagnostics. The information is further discussed with strategies for identifying predictive biomarkers to guide the clinical use of PD-1/PD-L1-targeted therapies.